BackAmbrx Biopharma Overview

Ambrx Biopharma Current Cash

Track Ambrx Biopharma's current cash ($230M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$225.26M
↑ 305.07% YoYΔ $169.65M vs prior year quarter

Peer trimmed avg / median

Loading

Ambrx Biopharma Current Cash History

Loading

Ambrx Biopharma vs. peers: Current Cash Comparison

Loading

Ambrx Biopharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ambrx Biopharma (AMAM) FAQ

As of the most recent data (September 2023), AMAM shows a current cash of $230M. That compares with $56M in the prior-year period — up 305.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMAM's current cash is now $230M (was $56M) — a 305.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Ambrx Biopharma is outperforming or lagging.

Tracking AMAM's current cash over time shows whether Ambrx Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $230M That compares with $56M in the prior-year period — up 305.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Ambrx Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $230M) with ownership activity and broader fundamentals.

Ambrx Biopharma's current cash is $230M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.